Tip 3 Diyabet
Özet
Alzheimer hastalığı (AH), merkezi sinir sisteminde bozulmuş insülin sinyal yolakları, insülin yetersizliği ve reseptör direnci nedeniyle ortaya çıkan nöroendokrin tabiatı sebebiyle "Tip 3 Diyabet" olarak adlandırılmaktadır. Yapılan araştırmalar; amiloid beta birikimi, tau proteini hiperfosforilasyonu, mitokondriyal disfonksiyon ve lipid peroksidasyonu gibi süreçlerin tetiklediği oksidatif stresin yanı sıra artan proinflamatuar sitokinler (IL-6, TNF-a) ve ileri glikasyon son ürünlerinin (AGE'ler) oluşturduğu kronik inflamasyonun bu patogenezde kritik rol oynadığını göstermektedir. Özellikle orta yaş dönemindeki abdominal obezite, insülin direnci ve metabolik sendrom, hipotalamik homeostazı bozarak ilerleyen yaşlarda AH riskini önemli ölçüde artırmaktadır. Tüm bu mekanizmalar sinaps kaybına ve bilişsel gerilemeye yol açarken, hastalığın sadece bir glukoz metabolizması bozukluğu olmadığını; genetik, hücresel ve metabolik faktörlerin bir bütünü olduğunu ortaya koymaktadır. Hücresel stres yolaklarının anti-diyabetik ajanlar ve küçük moleküllerle hedeflenmesi, gelecekteki tedavi stratejileri için umut vadetmektedir.
Alzheimer's disease (AD) is characterized as "Type 3 Diabetes" due to its neuroendocrine nature arising from impaired insulin signaling pathways, insulin deficiency, and receptor resistance within the central nervous system. Research indicates that chronic inflammation—driven by advanced glycation end-products (AGEs) and elevated proinflammatory cytokines (IL-6, TNF-a)—alongside oxidative stress triggered by amyloid-beta accumulation, tau protein hyperphosphorylation, mitochondrial dysfunction, and lipid peroxidation, plays a critical role in this pathogenesis. Particularly, midlife abdominal obesity, insulin resistance, and metabolic syndrome disrupt hypothalamic homeostasis, substantially increasing the risk of developing AD in later years. While these interconnected mechanisms culminate in synaptic loss and cognitive decline, they demonstrate that the disease is not merely a glucose metabolism disorder, but a complex integration of genetic, cellular, and metabolic factors. Consequently, targeting these cellular stress pathways with anti-diabetic agents and small molecule inhibitors reinforces therapeutic strategies for future interventions.
Referanslar
Pugazhenthi S, Qin L, Reddy PH. Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. Biochimica et biophysica acta (BBA)-Molecular Basis of Disease. 2017;1863(5):1037-45. doi: 10.1016/j.bbadis.2016.04.017
Kandimalla R, Reddy PH. Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2016;1862(4):814-28. doi: 10.1016/j.bbadis.2015.12.018
J Kandimalla R, Anand R, Veeramanikandan R, Yousuf Wani W, Prabhakar S, K Grover V, et al. CSF ubiquitin as a specific biomarker in Alzheimer's disease. Current Alzheimer research. 2014;11(4):340-8. doi: 10.2174/1567205011666140331161027
Binukumar B, Gupta N, Sunkaria A, Kandimalla R, Wani W, Sharma D, et al. Protective efficacy of coenzyme Q10 against DDVP-induced cognitive impairments and neurodegeneration in rats. Neurotoxicity research. 2012;21(4):345-57. doi: 10.1007/s12640-011-9289-0
Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2012;1822(5):639-49. doi: 10.1016/j.bbadis.2011.10.011
Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer's disease a type 3 diabetes? A critical appraisal. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2017;1863(5):1078-89. doi: 10.1016/j.bbadis.2016.08.018
Kroner Z. The Relationship between Alzheimer's Disease and Diabetes: Type 3 Diabetes. Alternative Medicine Review. 2009;14(4).
Iwangoff P, Armbruster R, Enz A, Meier-Ruge W. Glycolytic enzymes from human autoptic brain cortex: normal aged and demented cases. Mechanisms of ageing and development. 1980;14(1-2):203-9. doi: 10.1016/0047-6374(80)90120-7
Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Frontiers in Clinical Neuroscience. 2004:135-52. doi: 10.1007/978-1-4419-8969-7_8
Steen E, Terry BM, J Rivera E, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease–is this type 3 diabetes? Journal of Alzheimer's disease. 2005;7(1):63-80. doi: 10.3233/jad-2005-7107
Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. Journal of Alzheimer's disease. 2005;8(3):247-68. doi: 10.3233/jad-2005-8304
de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. Journal of Alzheimer's Disease. 2005;7(1):45-61. doi:
Freude S, Schilbach K, Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Current Alzheimer Research. 2009;6(3):213-23. doi: 10.2174/156720509788486527
de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Current opinion in investigational drugs (London, England: 2000). 2009;10(10):1049.
Cadigan KM, Liu YI. Wnt signaling: complexity at the surface. J Cell Sci. 2006;119(3):395-402. doi: 10.1242/jcs.02826
Tabatadze N, Tomas C, McGonigal R, Lin B, Schook A, Routtenberg A. Wnt transmembrane signaling and long‐term spatial memory. Hippocampus. 2012;22(6):1228-41. doi: 10.1002/hipo.20991
Varela-Nallar L, Inestrosa NC. Wnt signaling in the regulation of adult hippocampal neurogenesis. Frontiers in cellular neuroscience. 2013;7:100. doi: 10.3389/fncel.2013.00100
Woods SC, Seeley RJ, Baskin DG, Schwartz MW. Insulin and the blood-brain barrier. Current pharmaceutical design. 2003;9(10):795. doi: 10.2174/1381612033455323
Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J. 1998;333(3):471-90. doi: 10.1042/bj3330471
Lizcano JM, Alessi DR. The insulin signalling pathway. Current biology. 2002;12(7):R236-R8. doi: 10.1016/s0960-9822(02)00777-7
Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nature reviews Drug discovery. 2004;3(6):479-87. doi: 10.1038/nrd1415
Luchsinger JA, Tang M-X, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63(7):1187-92. doi: 10.1212/01.WNL.0000140292.04932.87
Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nature Reviews Neuroscience. 2015;16(6):358-72. doi: 10.1038/nrn3880
Wang X, Wang W, Li L, Perry G, Lee H-g, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2014;1842(8):1240-7. doi: 10.1016/j.bbadis.2013.10.015
Ahmad W. Overlapped metabolic and therapeutic links between Alzheimer and diabetes. Molecular neurobiology. 2013;47(1):399-424. doi: 10.1007/s12035-012-8352-z
Rousset S, Alves-Guerra M-C, Mozo J, Miroux B, Cassard-Doulcier A-M, Bouillaud F, et al. The biology of mitochondrial uncoupling proteins. Diabetes. 2004;53(suppl_1):S130-S5. doi: 10.2337/diabetes.53.2007.s130
Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. Journal of Diabetes and its Complications. 2001;15(4):203-10. doi: 10.1016/s1056-8727(01)00143-x
Pérez-Matute P, Zulet MA, Martínez JA. Reactive species and diabetes: counteracting oxidative stress to improve health. Current opinion in pharmacology. 2009;9(6):771-9. doi: 10.1016/j.coph.2009.08.005
Hotamisligil G. Inflammatory pathways and insulin action. International Journal of Obesity. 2003;27(3):S53-S5. doi: 10.1038/sj.ijo.0802502
Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? British journal of clinical pharmacology. 2011;71(3):365-76. doi: 10.1111/j.1365-2125.2010.03830.x
Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes. Proceedings of the National Academy of Sciences. 2010;107(15):7036-41. doi: 10.1073/pnas.1000645107
Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S-i, Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer’s disease. American Journal of Alzheimer's Disease & Other Dementias®. 2006;21(3):197-208. doi: 10.1177/1533317506289277
Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Archives of neurology. 2000;57(11):1586-91. doi: 10.1001/archneur.57.11.1586
Nakamura T, Furuhashi M, Li P, Cao H, Tuncman G, Sonenberg N, et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell. 2010;140(3):338-48. doi: 10.1016/j.cell.2010.01.001
Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, et al. TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer’s β-amyloid oligomers in mice and monkeys. Cell metabolism. 2013;18(6):831-43. doi: 10.1016/j.cmet.2013.11.002
Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. European journal of pharmacology. 2008;585(1):119-29. doi: 10.1016/j.ejphar.2008.02.048
Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biological psychiatry. 2010;67(6):505-12. doi: 10.1016/j.biopsych.2009.02.013
Dorner TE, Rieder A. Obesity paradox in elderly patients with cardiovascular diseases. International journal of cardiology. 2012;155(1):56-65. doi: 10.1016/j.ijcard.2011.01.076
Luchsinger JA, Patel B, Tang M-X, Schupf N, Mayeux R. Measures of adiposity and dementia risk in elderly persons. Archives of neurology. 2007;64(3):392-8. doi: 10.1001/archneur.64.3.392
Hildreth KL, Van Pelt RE, Schwartz RS. Obesity, insulin resistance, and Alzheimer’s disease. Obesity (Silver Spring, Md). 2012;20(8):1549. doi: 10.1038/oby.2012.19
Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Alam SE, et al. Metabolic syndrome: a brain disease. Canadian journal of physiology and pharmacology. 2012;90(9):1171-83. doi: 10.1139/y2012-122
Ojo O, Brooke J. Evaluating the association between diabetes, cognitive decline and dementia. International journal of environmental research and public health. 2015;12(7):8281-94. doi: 10.3390/ijerph120708281
Purkayastha S, Cai D. Neuroinflammatory basis of metabolic syndrome. Molecular metabolism. 2013;2(4):356-63. doi: 10.1016/j.molmet.2013.09.005
Bourdel-Marchasson I, Lapre E, Laksir H, Puget E. Insulin resistance, diabetes and cognitive function: consequences for preventative strategies. Diabetes & metabolism. 2010;36(3):173-81. doi: 10.1016/j.diabet.2010.03.001
